Common IBD drug tested as new hope for rare liver disease
NCT ID NCT03561584
Summary
This study tested whether sulfasalazine, a medication commonly used for inflammatory bowel disease (IBD), could help control primary sclerosing cholangitis (PSC), a rare liver disease. The trial involved 32 adults with both PSC and IBD across the US, who received either the drug or a placebo for 24 weeks. Researchers measured if the treatment safely reduced key markers of liver injury and improved patient symptoms like fatigue and itching.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Chestnut Hill, Massachusetts, 02467, United States
Conditions
Explore the condition pages connected to this study.